Krill oil, stevia, and caffeine are high-profile ingredients.
Revised monograph standards for krill oil, stevia, and caffeine are among the latest changes proposed for the Food Chemicals Codex (FCC) published by the U.S. Pharmacopeial Convention (USP). The FCC is a compendium of food ingredient quality standards. USP is calling for public comment on the proposed standards, published in the most recent FCC Forum.
Krill oil, stevia, and caffeine are high-profile ingredients, with krill oil and stevia seeing growing demand worldwide and with regulatory scrutiny surrounding caffeine-containing energy beverages.
For krill oil, the latest monograph proposes tests-both qualitative (fingerprint) and quantitative-for measuring total phospholipid content, including key phospholipid phosphatidylcholine. (When the monograph was first proposed in 2010, public comments recommended that such tests for phospholipids be included.) Krill phospholipids contain omega-3 fatty acids DHA and EPA, which have been linked to such health benefits as cardiovascular, joint, women’s, and brain health.
For stevia, the revised monograph is said to provide “a more simplified approach for separating and measuring all nine glycosides present in the stevia leaf.” This latest monograph-the first version was proposed in the FCC Forum in December 2011-includes these two new reference standards for stevia: the aforementioned Steviol Glycosides System Suitability standard for identifying and measuring the individual glycosides, as well as an already existing USP monograph for high-purity Rebaudioside A. USP says both are addressed because in addition to Reb A, which was the first stevia-based sweetener used in the United States and Europe, many stevia products now include mixtures of different glycosides.
Finally, for caffeine, the FCC proposes a “more discriminating liquid chromatography test for both identity and quantitative determination of the purity of caffeine content.” Alluding to recent negative regulatory attention on energy drinks, USP states, “With the potential for closer regulatory scrutiny of products high in caffeine content following alleged adverse events and consumer group petitions, companies will need to be confident that they know with greater precision what they are incorporating into their products-and in what quantity.” USP says the new FCC analytical method is based on an equivalent method published in the caffeine monograph in the USP 35–NF 30, which is USP’s compendia for pharmaceutical and excipient standards.
“Public standards defining the identity, quality, and purity of ingredients incorporated into finished products can be an important resource for manufacturers as they source ingredients from suppliers around the world, offering some assurance that they are receiving the ingredients they expect by providing public specifications to which they can be compared,” said V. Srini Srinivasan, PhD, USP’s executive vice president of global science and standards. “While important for all ingredients, it is especially crucial for high-value ingredients, including those linked to health benefits such as krill oil and so-called natural ingredients such as stevia, which manufacturers and consumers pay a premium for and are in high public demand.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.